Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma [20]

British Journal of Dermatology

Volumn 153, Issue 1, 2005, Pages 234-236

  Baltaci, M ^a   Fritsch, P ^a   Weber, F ^a   Tzankov, A ^b   Sognert P ^a   Derler, A M ^a   Hopel R ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADVANCED CANCER; AGED; ANAMNESIS; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MALE; PRIORITY JOURNAL; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TELANGIECTASIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FACIAL NEOPLASMS; HUMANS; MALE; QUINAZOLINES; SKIN NEOPLASMS;

EID: 22944448055     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06709.x     Document Type: Letter

References (10)

1. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as marker of treatment outcome? Oncology 2003; 17 (Suppl. 12):23-8.
2. Sweeney C, Carraway KL 3rd Negative regulation of ErbB family receptor tyrosine kinases. Br J Cancer 2004; 26:289-93.
3. Barker AJ, Gibson KH, Grundy W et al. Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911-14.
4. Cohen EE, Rosen F, Stadier WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 15:1980-7.
5. von Pawel J. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer 2004; 91: 70-6.
6. Dawson NA, Guo C, Zak R et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 2004; 10:7812-19.
7. Hopfner M, Sutter AP, Huether A et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004; 41:1008-16.
8. Nanney LB, Magid M, Stoscheck CM, King LE Jr. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83:385-93.
9. Grünwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95:851-67.
10. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet 2003; 362:62-4.